Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Director Sells $1,421,177.84 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYGet Rating) Director Jack Nielsen sold 24,898 shares of Harmony Biosciences stock in a transaction dated Monday, November 21st. The stock was sold at an average price of $57.08, for a total value of $1,421,177.84. Following the sale, the director now owns 2,846,163 shares in the company, valued at approximately $162,458,984.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jack Nielsen also recently made the following trade(s):

  • On Friday, November 18th, Jack Nielsen sold 20,800 shares of Harmony Biosciences stock. The stock was sold at an average price of $57.00, for a total value of $1,185,600.00.
  • On Monday, November 14th, Jack Nielsen sold 58,667 shares of Harmony Biosciences stock. The stock was sold at an average price of $58.70, for a total value of $3,443,752.90.

Harmony Biosciences Price Performance

Shares of HRMY opened at $57.50 on Friday. Harmony Biosciences Holdings, Inc. has a twelve month low of $31.54 and a twelve month high of $61.55. The stock’s 50 day moving average is $51.04 and its two-hundred day moving average is $48.55. The firm has a market capitalization of $3.41 billion, a PE ratio of 22.46 and a beta of 0.52. The company has a current ratio of 3.56, a quick ratio of 3.52 and a debt-to-equity ratio of 0.55.

Harmony Biosciences (NASDAQ:HRMYGet Rating) last announced its quarterly earnings data on Tuesday, November 1st. The company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.85. Harmony Biosciences had a return on equity of 62.83% and a net margin of 38.84%. The company had revenue of $117.21 million for the quarter, compared to analyst estimates of $113.11 million. Research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Mizuho lifted their target price on Harmony Biosciences from $60.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, November 8th. Jefferies Financial Group upgraded Harmony Biosciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $57.00 to $61.00 in a research report on Friday, October 14th. They noted that the move was a valuation call. Raymond James boosted their price target on Harmony Biosciences from $60.00 to $62.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. Oppenheimer boosted their price target on Harmony Biosciences from $62.00 to $67.00 and gave the company an “outperform” rating in a research report on Wednesday, August 3rd. Finally, Janney Montgomery Scott upgraded Harmony Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $57.00 to $61.00 in a research report on Friday, October 14th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $62.50.

Institutional Investors Weigh In On Harmony Biosciences

A number of institutional investors have recently added to or reduced their stakes in HRMY. BlackRock Inc. boosted its stake in shares of Harmony Biosciences by 20.9% during the 3rd quarter. BlackRock Inc. now owns 4,802,113 shares of the company’s stock worth $212,685,000 after acquiring an additional 829,234 shares in the last quarter. Polar Capital Holdings Plc purchased a new stake in shares of Harmony Biosciences during the 1st quarter worth approximately $26,758,000. FMR LLC boosted its stake in shares of Harmony Biosciences by 10.8% during the 2nd quarter. FMR LLC now owns 5,426,782 shares of the company’s stock worth $264,664,000 after acquiring an additional 529,600 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Harmony Biosciences during the 3rd quarter worth approximately $18,653,000. Finally, Lisanti Capital Growth LLC purchased a new stake in shares of Harmony Biosciences during the 2nd quarter worth approximately $14,820,000. Hedge funds and other institutional investors own 81.24% of the company’s stock.

About Harmony Biosciences

(Get Rating)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Further Reading

Insider Buying and Selling by Quarter for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.